TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Down 29.9% in November

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 21,100 shares, a drop of 29.9% from the November 15th total of 30,100 shares. Based on an average daily trading volume, of 16,300 shares, the days-to-cover ratio is presently 1.3 days. Currently, 0.2% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on TherapeuticsMD in a report on Sunday. They issued a “hold” rating for the company.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Stock Performance

Shares of NASDAQ:TXMD opened at $1.22 on Friday. TherapeuticsMD has a 1 year low of $1.15 and a 1 year high of $2.75. The business has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.68.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.